Table 2 Results from multivariate GEE model to identify predictors of response

Age at baseline, years

−0.003 (−0.01, 0.004)

0.35

RA duration, years

0.001 (−0.01, 0.008)

0.84

Sex, male^a/female

−0.13 (−0.41, 0.16)

0.39

DAS28 at baseline

0.39 (0.30, 0.49)

<0.0005

Duration of anti-TNF therapy, weeks

0.02 (0.01, 0.03)

<0.0005

RAPA seropositivity, yes/no^a

−0.07 (−0.39, 0.25)

0.66

ACPA seropositivity, yes/no^a

0.10 (−0.28, 0.48)

0.61

Smoking status, never^a/past/current

−0.10 (−0.24, 0.05)

0.18

Concurrent methotrexate use, yes/no^a

0.43 (0.19, 0.68)

<0.0005

Concurrent prednisolone use, yes/no^a

−0.08 (−0.28, 0.11)

0.40

Type of anti-TNF therapy, ETN^a, ADA or INF

−0.08 (−0.18, 0.02)

0.12